Sarepta Therapeutics (NASDAQ:SRPT) Posts Earnings Results, Misses Expectations By $2.71 EPS

Sarepta Therapeutics (NASDAQ:SRPT) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71), FiscalAI reports. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. During the same period in the prior year, the company earned $1.90 earnings per share. The business’s revenue was down 32.7% on a year-over-year basis.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• Ended 2025 with $954 million in cash and investments and expects to be cash‑flow positive and non‑GAAP profitable in 2026 while maintaining pipeline and commercial investments (2026 non‑GAAP OpEx guide $800–$900M).
• ELEVIDYS uncertainty has largely been addressed (updated label/traditional approval for ambulatory 4+), and a sirolimus pretreatment study for non‑ambulatory patients is enrolling, but persistent patient/physician hesitancy and long enrollment‑to‑infusion timelines are expected to dampen near‑term ELEVIDYS revenue and drove conservative 2026 guidance.
• The PMO franchise remained durable (Q4 PMO revenue $259M) with >90% compliance and strong real‑world evidence; Sarepta has a late‑Q1 FDA meeting and briefing book to pursue transitioning AMONDYS and VYONDYS to traditional approvals based on ESSENCE and long‑term safety data.
• Sarepta’s siRNA pipeline advanced to five clinical‑stage programs (DM1, FSHD, IPF, SCA2, Huntington); preliminary DM1/FSHD PK/PD/proof‑of‑concept data are expected by quarter‑end with multiple value‑creating milestones over the next 12–18 months.
• CEO Doug Ingram said he intends to retire around the end of 2026 and the board has launched an internal and external search, creating near‑term succession and execution risk.

Sarepta Therapeutics Trading Up 0.7%

Sarepta Therapeutics stock traded up $0.13 during trading hours on Wednesday, hitting $18.97. The stock had a trading volume of 2,218,922 shares, compared to its average volume of 2,082,896. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $109.55. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The company has a 50-day moving average of $20.61 and a two-hundred day moving average of $20.25.

Insider Activity at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. This represents a 6.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently bought and sold shares of the business. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Sarepta Therapeutics by 340.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 95,752 shares of the biotechnology company’s stock valued at $2,061,000 after buying an additional 74,027 shares during the period. EP Wealth Advisors LLC acquired a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $213,000. Mackenzie Financial Corp grew its stake in shares of Sarepta Therapeutics by 17.1% in the fourth quarter. Mackenzie Financial Corp now owns 58,042 shares of the biotechnology company’s stock valued at $1,245,000 after buying an additional 8,494 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in Sarepta Therapeutics by 166.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 31,741 shares of the biotechnology company’s stock worth $683,000 after buying an additional 19,830 shares during the last quarter. Finally, Millennium Management LLC raised its position in Sarepta Therapeutics by 251.9% during the fourth quarter. Millennium Management LLC now owns 1,000,109 shares of the biotechnology company’s stock worth $21,522,000 after acquiring an additional 715,899 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wells Fargo & Company decreased their price target on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Wall Street Zen lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Guggenheim reduced their target price on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Robert W. Baird dropped their price target on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Finally, Royal Bank Of Canada upped their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Thursday, January 8th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.